Human Beta Defensin 2 Modulation of TNF-Alpha in Rheumatoid Arthritis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatoid arthritis lack effective solutions to reduce inflammation and manage the disease's progression, particularly in addressing TNF-alpha activity, which is a key factor in the disorder's chronicity and severity.
Innovation Solution
Administration of human beta defensins, specifically human beta defensin 2, which has been shown to significantly reduce the severity of disease parameters in collagen-induced rheumatoid arthritis models by modulating cytokine profiles and reducing TNF-alpha activity, thereby offering a novel therapeutic approach for treating and potentially preventing the disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for rheumatoid arthritis are used, then disease management is maintained at conventional levels, but TNF-alpha activity and inflammation are not effectively reduced
Solution Approach 1:
The patent applies parameter changes by introducing human beta defensins (specifically hBD-2) as a novel therapeutic agent with different biochemical properties compared to conventional treatments. The defensins modify the inflammatory response parameters by downregulating pro-inflammatory cytokines and upregulating anti-inflammatory cytokines, thereby changing the therapeutic parameters to achieve better control of TNF-alpha activity and inflammation in rheumatoid arthritis
Solution Approach 2:
The patent uses human beta defensins as intermediary molecules that mediate the therapeutic effect between the administered substance and the pathological process. The defensins act as intermediaries by directly interacting with immune cells and inflammatory pathways, modulating cytokine production and reducing TNF-alpha activity, thus serving as a bridging mechanism between treatment administration and disease modification
2Object-affected harmful factors
If human beta defensin 2 is administered, then TNF-alpha activity and inflammation are reduced, but the complexity of the therapeutic approach increases
Solution Approach 1:
The patent extracts and utilizes the specific anti-inflammatory and immunomodulatory properties of human beta defensin 2 from its natural context. By isolating and administering hBD-2 as a purified therapeutic agent, the patent extracts the beneficial effects (reduced inflammation and TNF-alpha activity) while simplifying the treatment approach to a targeted molecular therapy, despite the initial perception of increased complexity
Solution Approach 2:
The patent demonstrates the multi-functionality of human beta defensin 2, which simultaneously performs multiple therapeutic functions: it reduces pro-inflammatory cytokines, upregulates anti-inflammatory cytokines, directly inhibits TNF-alpha activity, and modulates immune cell responses. This multi-functional approach consolidates multiple therapeutic effects into a single agent, thereby reducing overall treatment complexity rather than increasing it
Data Source
AI summary
The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.